Resection of a primary breast tumor can leave quiescent disseminated cancer cells (DCCs) in distant organs that reawaken years to decades later as lethal metastases. A 2021 study showed that tumor-primed CD39+PD-1+CD8+ T cells, including tissue-resident memory cells, hold disseminated breast cancer cells dormant in the lung through IFNγ- and TNFα-mediated cell-cycle arrest, yet cannot fully eradicate them, and asked which processes awaken dormant cells after long latency, whether attrition or functional alteration of this T-cell population underlies relapse, how durable the program is without persistent antigen, whether dormant cells can evade cytokine-induced senescence, how general the mechanism is across organs and subtypes, and which pathways must be mobilized to eliminate DCCs. Follow-up work has resolved part of this in the original mouse model (induction requires CD4 help and IFNγ; maintenance is T-cell independent; CD4-derived IL-17A is an essential inflammatory wake-up signal), respiratory-virus infection was identified as an interleukin-6-dependent awakening cue with human observational support, and immune dormancy was extended to triple-negative models via CXCL10/CXCR3, but the human mechanisms of decade-scale latency, senescence evasion, cross-organ and cross-subtype generality, and therapeutic eradication of dormant DCCs remain open.

Background

Breast cancer kills mainly through late metastatic relapse: cells that leave the primary tumor before surgery, called disseminated cancer cells (DCCs), can lodge in distant organs in a non-dividing state known as metastatic dormancy, and re-enter the cell cycle months to decades later to found overt metastases. Dormancy has two idealized forms — single quiescent cells, and small cell masses held stable by a balance of proliferation and death — and understanding what maintains and what breaks dormancy is the central obstacle to preventing late relapse. A key discovery of Tallón de Lara and colleagues (Nature Communications, 2021) is that dormancy can be actively immune-mediated: in BALB/c mice bearing the 4T07 breast cancer line (which disseminates to the lung but rarely forms overt metastases, unlike its aggressive sister line 4T1), the primary tumor primes a systemic CD8+ T-cell response whose PD-1+CD39+ fraction holds the lung DCCs dormant. PD-1 is the exhaustion/activation checkpoint receptor marking recently antigen-stimulated T cells; CD39 is an ectonucleotidase (an enzyme on the cell surface that degrades extracellular ATP) that marks tumor-primed, antigen-specific CD8+ T cells; a fraction of these cells express CD103, a marker of tissue-resident memory T cells (Trm), which persist in tissues rather than recirculating. Mechanistically, these T cells produce interferon-γ (IFNγ) and tumor necrosis factor α (TNFα), cytokines that can push DCCs into an irreversible growth-arrested state termed cytokine-induced senescence. In patients, high density of intratumoral CD39+PD-1+CD8+ T cells correlated with disease-free survival after resection, including in the less immune-infiltrated luminal A/B subtypes (hormone-receptor-positive, molecularly defined and generally more indolent breast cancer subtypes); human single-cell work concurrently found that CD39hi tissue-resident memory CD8+ T cells predict positive prognosis in luminal-like breast cancer. Crucially, however, the T cells arrested but did not eliminate all DCCs, and the authors' discussion left a structured set of open questions: why dormant cells sometimes awaken only after decades; whether attrition or functional alteration of the tissue-resident CD39+PD-1+CD8+ pool (known to be unstable without persistent antigen) permits awakening, or whether the dormant cells themselves change, for example losing molecules required for immune-mediated senescence; how environmental insults (fibrosis, inflammation, tissue remodeling, obesity, stress hormones) induce cycling and whether immunity can interfere; and which pathways must be mobilized therapeutically to completely eliminate rather than merely arrest DCCs. Subsequent work has materially advanced the model-level picture: in the same 4T07 system the Zurich group showed that induction of dormancy requires CD4+ T-cell help for the protective CD8+ differentiation and that IFNγ acts directly on DCCs, that dormancy, once established, is maintained without continuous lymphocyte surveillance, and that awakening requires an inflammatory signal delivered by CD4+ T-cell-derived interleukin-17A (IL-17A); respiratory viral infections (influenza and SARS-CoV-2) were likewise shown to awaken dormant lung DCCs in mice within days through interleukin-6-dependent inflammation, with human observational data indicating that SARS-CoV-2 infection raises cancer-related mortality and lung-metastasis risk in cancer survivors; in triple-negative (estrogen-receptor-, progesterone-receptor-, and HER2-negative) breast cancer models the interferon-inducible chemokine CXCL10 (a secreted immune-attractant signaling protein) and its receptor CXCR3 were shown to be required to sustain immune-dependent dormancy, with a CXCL10 dormancy signature predicting survival of triple-negative breast cancer patients; during micrometastatic outbreak, TIM3-expressing tumor cells (TIM3 being the T-cell immunoglobulin and mucin domain 3 receptor, here acting tumor-intrinsically) were selected and drove stemness and immune evasion; dormant tumor cells were shown to build a protective Treg (regulatory T cell) niche via the secreted Wnt-pathway inhibitor DKK3 despite remaining antigen-visible; and intratumoral priming of CD4+ T helper 1 (Th1) cells (a CD4+ effector lineage that secretes interferon-γ) was reported to eradicate DCC burden in distant organs in an IFNγ-dependent, CD8-independent manner. Reviews through 2026 nonetheless treat the triggers of awakening, the escape from immune control, and the choice between sustaining dormancy and eliminating dormant cells as open field-level problems.

Problem Statement

The problem is to close the mechanistic and translational gap left by the discovery that tumor-primed CD39+PD-1+CD8+ T cells (including tissue-resident memory cells) hold disseminated breast cancer cells dormant through IFNγ/TNFα-mediated senescence yet cannot eliminate them. Specifically: (1) determine which physiological or pathological processes cause dormant disseminated cancer cells to re-enter the cell cycle after long latency — in the original 4T07 lung model a CD4+ T-cell-derived IL-17A inflammatory signal was identified as necessary for awakening, and respiratory viral infection was shown to awaken dormant lung DCCs in mice in an interleukin-6-dependent manner with supportive human observational data, so the remaining question is whether inflammatory, aging-related, or other microenvironmental cues drive awakening in patients over years to decades, and how multiple converging routes interact; (2) establish whether awakening reflects attrition or functional alteration of the protective T-cell population (given that maintenance was shown to be T-cell independent in the 4T07 model, determine what, if any, role loss of the CD39+PD-1+CD8+ program without persistent antigen plays) versus cell-intrinsic changes of the dormant cells, including loss of antigenicity or increased immune-inhibitory ligand expression that abolish susceptibility to IFNγ/TNFα-induced senescence; (3) establish the generality of immune-mediated dormancy across tumor models, colonized organs (lung, bone marrow, brain, and other sites), and human breast cancer subtypes, moving from the mouse models already characterized (4T07; D2.0R and 4T1-MR20 with the CXCL10/CXCR3 axis) to patient material; and (4) identify the pathways that must be mobilized therapeutically — for example T-cell or innate programs, cytokine or chemokine axes, or niche targets — to convert dormancy into complete elimination of disseminated cancer cells without harming normal tissue, and demonstrate this eradication in clinically relevant systems. The four strands above are independent sub-questions; strand (4) calls for a concrete, testable experimental or clinical strategy rather than the execution of new experiments.

References

  1. Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdinez J, Cecconi V, Yagita H, Movahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, van den Broek M. CD39+PD-1+CD8+ T cells mediate metastatic dormancy in breast cancer. Nature Communications 12, 769 (2021). DOI: 10.1038/s41467-021-21045-2. https://doi.org/10.1038/s41467-021-21045-2
  2. Pereira P, Panier J, Nater M, Herbst M, Calvanese AL, Köksal H, Castañón H, Cecconi V, Tallón de Lara P, Pascolo S, van den Broek M. Inflammatory cytokines mediate the induction of and awakening from metastatic dormancy. Cell Reports 44(3), 115388 (2025). DOI: 10.1016/j.celrep.2025.115388. https://doi.org/10.1016/j.celrep.2025.115388
  3. Yilmaz A, Haerri L, Granda ME, Coquoz O, Lan Q, Rüegg C. The CXCL10/CXCR3 axis is essential for sustaining immunological dormancy in triple-negative breast cancer. npj Breast Cancer 12, 36 (2026). DOI: 10.1038/s41523-026-00903-6. https://doi.org/10.1038/s41523-026-00903-6
  4. Chia SB, Johnson BJ, Hu J, Valença-Pereira F, Chadeau-Hyam M, Guntoro F, Montgomery H, Boorgula MP, Sreekanth V, Goodspeed A, Davenport B, De Dominici M, Zaberezhnyy V, Schleicher WE, Gao D, Cadar AN, Petriz-Otaño L, Papanicolaou M, Beheshti A, Baylin SB, Guarnieri JW, Wallace DC, Costello JC, Bartley JM, Morrison TE, Vermeulen R, Aguirre-Ghiso JA, Rincon M, DeGregori J. Respiratory viral infections awaken metastatic breast cancer cells in lungs. Nature 645, 496–506 (2025). DOI: 10.1038/s41586-025-09332-0. https://doi.org/10.1038/s41586-025-09332-0
  5. Rozalén C, Sangrador I, Avalle S, Blasco-Benito S, Tzortzi P, Sanz-Flores M, Palomeque JÁ, Torren-Duran P, Dalmau M, Brunel H, Coll-Manzano A, Pérez-Núñez I, Martos T, Servitja S, Pérez-Buira S, Chacón JI, Guerrero-Zotano Á, Martínez de Dueñas E, Guillén Y, Comerma L, Bermejo B, Bigas A, Casanova-Acebes M, Alemany A, Rojo F, Albanell J, Celià-Terrassa T. TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak. Cancer Cell 43(8), 1549–1567.e9 (2025). DOI: 10.1016/j.ccell.2025.06.015. https://doi.org/10.1016/j.ccell.2025.06.015
  6. Trotter TN, Dagotto CE, Serra D, Wang T, Yang X, Acharya CR, Wei J, Lei G, Lyerly HK, Hartman ZC. Dormant tumors circumvent tumor-specific adaptive immunity by establishing a Treg-dominated niche via DKK3. JCI Insight 8(22), e174458 (2023). DOI: 10.1172/jci.insight.174458. https://doi.org/10.1172/jci.insight.174458
  7. Ramamoorthi G, Lee MC, Farrell CM, Snyder C, Garg SK, Aldrich AL, Lok V, Dominguez-Viqueira W, Olson-Mcpeek SK, Rosa M, Gautam N, Pilon-Thomas S, Cen L, Kodumudi KN, Wiener D, Oskarsson T, Gomes AP, Gatenby RA, Czerniecki BJ. Antitumor CD4+ T Helper 1 Cells Target and Control the Outgrowth of Disseminated Cancer Cells. Cancer Immunology Research 13(5), 729–748 (2025). DOI: 10.1158/2326-6066.cir-24-0630. https://doi.org/10.1158/2326-6066.cir-24-0630
  8. Tallón de Lara P, Castañón H, Sterpi M, van den Broek M. Antimetastatic defense by CD8+ T cells. Trends in Cancer 8(2), 145–157 (2022). DOI: 10.1016/j.trecan.2021.10.006. https://doi.org/10.1016/j.trecan.2021.10.006
  9. Losurdo A, Scirgolea C, Alvisi G, Brummelman J, Errico V, Di Tommaso L, Pilipow K, Colombo FS, Fernandes B, Peano C, Testori A, Tinterri C, Roncalli M, Santoro A, Mazza EMC, Lugli E. Single-cell profiling defines the prognostic benefit of CD39high tissue resident memory CD8+ T cells in luminal-like breast cancer. Communications Biology 4, 1117 (2021). DOI: 10.1038/s42003-021-02595-z. https://doi.org/10.1038/s42003-021-02595-z
  10. Hill SL, Sugiyarto G, Harrington J, James E, Underwood TJ, Elliott T. High proportion of PD-1 and CD39 positive CD8+ tissue resident T lymphocytes correlates with better clinical outcome in resected human oesophageal adenocarcinoma. Cancer Immunology, Immunotherapy 73(11), 213 (2024). DOI: 10.1007/s00262-024-03799-y. https://doi.org/10.1007/s00262-024-03799-y
  11. Bodogai M, Park B, Braikia FZ, Naqing F, Kumaraswami K, Chen C, Ragonnaud E, Stack S, Ormanns S, Günther M, Ishikawa-Ankerhold H, De S, Ferrucci L, Sen R, Duren Z, Beerman I, Biragyn A. A distinct population of CD8+ T cells expressing CD39 and CD73 accumulates with age and supports cancer progression. Nature Aging 5(10), 2055–2069 (2025). DOI: 10.1038/s43587-025-00966-3. https://doi.org/10.1038/s43587-025-00966-3
  12. Zhang J, Khalil MI, Mishra R, Li H, Perelli L, Weinberg RA. Intrinsic and extrinsic regulators of cancer dormancy and awakening. Journal of the National Cancer Center 6(3), 211–218 (2026). DOI: 10.1016/j.jncc.2026.03.007. https://doi.org/10.1016/j.jncc.2026.03.007
  13. Liang Y, Chen WM, Zhang Y, Li L. Remodeling the tumor dormancy ecosystem to prevent recurrence and metastasis. Signal Transduction and Targeted Therapy 11, 1 (2026). DOI: 10.1038/s41392-025-02328-2. https://doi.org/10.1038/s41392-025-02328-2
  14. Liu W, Kovacs AH, Hou J. Cancer Cells in Sleep Mode: Wake Them to Eliminate or Keep Them Asleep Forever? Cells 13(23), 2022 (2024). DOI: 10.3390/cells13232022. https://doi.org/10.3390/cells13232022
  15. Pereira P, Cecconi V, van den Broek M. Protocol to study metastatic dormancy using 4T07-mCherry breast cancer cells and an algorithm-based quantification of disseminated cancer cells. STAR Protocols 6(4), 104182 (2025). DOI: 10.1016/j.xpro.2025.104182. https://doi.org/10.1016/j.xpro.2025.104182